Novacyt (LON:NCYT) Trading Down 9.2% – What’s Next?

Novacyt S.A. (LON:NCYT) fell 9.2% on Wednesday . The stock traded as low as GBX 55 and last traded at GBX 55.60. 1,811,013 shares were traded during trading, an increase of 618% from the average session volume of 252,315 shares. The stock had previously closed at GBX 61.20.

Novacyt Trading Down 4.1%

The company has a fifty day simple moving average of GBX 36.74 and a two-hundred day simple moving average of GBX 36.48. The company has a debt-to-equity ratio of 44.73, a current ratio of 4.74 and a quick ratio of 4.46. The company has a market capitalization of £34.75 million, a P/E ratio of -1.12 and a beta of 0.97.

Novacyt (LON:NCYT) last posted its earnings results on Thursday, April 30th. The company reported GBX (33) earnings per share for the quarter. The company had revenue of GBX 2,003 million for the quarter. Novacyt had a negative net margin of 135.96% and a negative return on equity of 111.34%.

Novacyt Company Profile

Novacyt is an international molecular diagnostics company providing a broad portfolio of integrated technologies and services, primarily focused on the delivery of genomic medicine. The Company develops, manufactures, and commercialises a range of molecular assays and instrumentation to deliver workflows and services that enable seamless end-to-end solutions from sample to result across multiple sectors including human health, animal health and environmental.

The Company is divided into three business segments:

Clinical
Broad portfolio of human clinical in vitro diagnostic products, workflows and services focused on three therapeutic areas:
· Reproductive Health: NIPT, Cystic Fibrosis and other rapid aneuploidy tests
· Precision Medicine: DPYD genotyping assay
· Infectious Diseases: Winterplex, multiplex winter respiratory PCR panel

Instrumentation
Portfolio of next generation size selection DNA sample preparation platforms and rapid PCR machines, including:
· Ranger® Technology: automated DNA sample preparation and target enrichment technology
MyGo: real-time quantitative PCR (qPCR) instruments

Research Use Only
Range of services for the life sciences industry:
· Design, manufacture, and supply of high-performance qPCR assays and workflows for use in human health, agriculture, veterinary and environmental, to support global health organisations and the research industry
· Pharmaceutical research services: whole genome sequencing (WGS) / whole exome sequencing (WES)

Novacyt is headquartered in Vélizy-Villacoublay in France with offices in the UK (in Stokesley, Eastleigh and Manchester), Taipei, Singapore, the US and Canada and has a commercial presence in over 65 countries.